Registered Charity 1114037

Welcome to cmlsupport.org.uk

Make a fundraising page JustGiving The CML Support Group is an online patient support group for chronic myeloid leukaemia patients, their families and carers. The website has been running since April 2000 and has a lively discussion forum as well as information regarding current therapies for CML.

Drugs to Avoid in Patients on Tyrosine Kinase Inhibitors

Megan Brooks July 25, 2014

With the rapid and widespread uptake of tyrosine kinase inhibitors (TKIs) in oncology over the past several years, serious drug–drug interactions are an "increasing risk," according a new report.
To guarantee the safe use of TKIs, "a drugs review for each patient is needed," write Frank G.A. Jansman, PharmD, PhD, from Deventer Hospital in the Netherlands, and colleagues in a review published in the July issue of the Lancet Oncology.
The review provides a comprehensive overview of known and suspected interactions between TKIs and conventional prescribed drugs, over-the-counter drugs, and herbal medicines.

http://www.medscape.com/viewarticle/828887?src=rss

Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib

Amina Haouala1, Nicolas Widmer1, Michel A. Duchosal2, Michael Montemurro3, Thierry Buclin1, and Laurent A. Decosterd1

Abstract

Several cancer treatments are shifting from traditional, time-limited, nonspecific cytotoxic chemotherapy cycles to continuous oral treatment with specific protein-targeted therapies. In this line, imatinib mesylate, a selective tyrosine kinases inhibitor (TKI), has excellent efficacy in the treatment of chronic myeloid leukemia. It has opened the way to the development of additional TKIs against chronic myeloid leukemia, including nilotinib and dasatinib. TKIs are prescribed for prolonged periods, often in patients with comorbidities. Therefore, they are regularly co-administered along with treatments at risk of drug-drug interactions. This aspect has been partially addressed so far, calling for a comprehensive review of the published data. We review here the available evidence and pharmacologic mechanisms of interactions between imatinib, dasatinib, and nilotinib and widely prescribed co-medications, including known inhibitors or inducers of cytochromes P450 or drug transporters. Information is mostly available for imatinib mesylate, well introduced in clinical practice. Several pharmacokinetic aspects yet remain insufficiently investigated for these drugs. Regular updates will be mandatory and so is the prospective reporting of unexpected clinical observations.

full article:
http://www.bloodjournal.org/content/117/8/e75.full?sso-checked=1

Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia

Ghalaut VS1, Sangwan L, Dahiya K, Ghalaut PS, Dhankhar R, Saharan R.

Abstract
Nitric oxide (NO) is involved in different stages of malignancies. Increased levels of NO have been reported in different leukemias. Imatinib is the preferred drug for the treatment of chronic myeloid leukemia (CML). Turmeric powder contains curcumin which has anti-leukemic property and also decreases NO synthesis. This study was conducted on fifty patients of CML divided into two groups, group A receiving imatinib alone and group B receiving turmeric powder along with imatinib for six weeks. Nitric oxide levels were estimated in these patients before and after receiving therapy and were analyzed statistically. Nitric oxide levels were found to be significantly decreased in both the groups, but more significantly in group B after receiving the respective treatments. Thus, curcumin acts as an adjuvant to imatinib in decreasing the NO levels and may help in the treatment of CML patients.
PMID: 21844132 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/pubmed/21844132

MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure

M Agrawal1, B Hanfstein1, P Erben1, D Wolf2, T Ernst3, A Fabarius1, S Saussele1, D Purkayastha4, R C Woodman4, W-K Hofmann1, R Hehlmann1, A Hochhaus3 and M C Müller1

Nilotinib was able to impede proliferation of MDR1-overexpressing imatinib-resistant cells. High MDR1 gene expression might identify patients whose mode of imatinib resistance is essentially determined by increased efflux activity of MDR1 and therefore can be overcome by second-line nilotinib treatment.

http://www.nature.com/leu/journal/v28/n7/abs/leu20146a.html?WT.ec_id=LEU...

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib

Timothy P. Hughes1,*, Jeffrey H. Lipton2, Nelson Spector3, Francisco Cervantes4, Ricardo Pasquini5, Nelma Cristina D. Clementino6, Pedro Enrique Dorlhiac Llacer7, Anthony P. Schwarer8, Francois-Xavier Mahon9, Delphine Rea10, Susan Branford11, Das Purkayastha12, LaTonya Collins12, Tomasz Szczudlo12, and Brian Leber13

Key Points
* Nilotinib induced deeper molecular responses than continued imatinib in patients with minimal residual disease on long-term imatinib.
* These deeper responses may enable more patients to benefit from treatment-free remission trials.

http://bloodjournal.hematologylibrary.org/content/early/2014/06/19/blood...

Copyright © 2014 American Society of Hematology

Managing children with chronic myeloid leukaemia (CML) Recommendations for the management of CML in children and young people up to the age of 18 years

Josu de la Fuente,1 Andre Baruchel,2 Andrea Biondi,3 Eveline de Bont,4 Marie-Francoise Dresse,5 Meinolf Suttorp6 and
Frederic Millot7 on behalf of the International BFM Group (iBFM) Study Group Chronic Myeloid Leukaemia Committee

Paediatrics Department, Saint Mary Hospital, London, UK, 2Department of Paediatric Haematology, Hopital Robert Debre, Paris,
France, 3 M. Tettamanti Research Centre, Paediatrics Department, University of Milano-Bicocca, Monza, Italy, 4 Department of Paediatric Oncology, Beatrix Children’s Hospital, Groningen, the Netherlands, 5 Department of Paediatric Haematology-Oncology, CHR La Citadelle, Liege, Belgium, 6
Department of Paediatric Haematology & Oncology, University Hospital, Technical University Dresden, Dresden, Germany and 7 Department of Paediatric Oncology, CHU Poitiers, Poitiers, France

http://onlinelibrary.wiley.com/doi/10.1111/bjh.12977/pdf

Key Questions in CAR T-Cell Therapies

Jane de Lartigue, PhD Published Online: Monday, May 12, 2014

Renier J. Brentjens, MD, PhD, director of Cellular Therapeutics at Memorial Sloan Kettering (MSK) Cancer Center, focuses on the development of new therapies for patients with acute and chronic leukemias, in particular on novel immunotherapies such as chimeric antigen receptor (CAR) T cells. He is one of the founders of Juno Therapeutics, a start-up company launched in 2013 to expand cell-based immunotherapies, including CD19-targeted CAR T cells, into multiple cancer types. Brentjens, who is the director of Cellular Therapeutics at Memorial Sloan Kettering Cancer Center, discussed his research in this interview with OncologyLive.

- See more at: http://www.onclive.com/publications/Oncology-live/2014/April-2014/Brentj...

A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive onco-kinases

F Hayakawa1, K Sugimoto1,2, Y Harada2, N Hashimoto2, N Ohi2, S Kurahashi1 and T Naoe1

"Here, we demonstrated that a novel STAT3 inhibitor, OPB-31121, strongly inhibited not only STAT3 but also STAT5 phosphorylation. OPB-31121 did not inhibit activities of kinases including JFKs and SFKs and its exact mechanism of action is under investigation; however, it induced significant growth inhibition in a wide range of hematopoietic malignant cells. Investigation among various cell lines indicated that this compound was particularly effective against multiple myeloma and Burkitt lymphoma, and leukemia harboring BCR–ABL,

http://www.nature.com/bcj/journal/v3/n11/full/bcj201363a.html

http://www.news.com.au/technology/science/sahmri-and-university-of-adela...

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline

Susan Branford1,*, David T. Yeung2, Wendy T. Parker1, Nicola D. Roberts1, Leanne Purins1, Jodi A. Braley1, Haley K. Altamura1, Alexandra L. Yeoman1, Jasmina Georgievski1, Bronte A. Jamison1, Stuart Phillis1, Zoe Donaldson1, Mary Leong1, Linda Fletcher1, John F. Seymour3, Andrew P. Grigg4, David M. Ross5, and Timothy P. Hughes6

Key Points

Among patients with >10% BCR-ABL1 at 3 months the poorest risk group can be distinguished by the rate of BCR-ABL1 decline from baseline.
Patients with BCR-ABL1 values on a constant downward trajectory may rapidly reach the level considered optimal with additional follow up.

http://bloodjournal.hematologylibrary.org/content/early/2014/05/23/blood...

Syndicate content